Willingdon Wealth Management Stake in Johnson & Johnson (JNJ) Lowered as Market Valuation Declined; As Biogen Idec (BIIB) Share Value Declined, Cullinan Associates Lifted Stake by $1.75 Million

Biogen Inc. (NASDAQ:BIIB) Logo

Cullinan Associates Inc increased its stake in Biogen Idec (BIIB) by 49.21% based on its latest 2018Q4 regulatory filing with the SEC. Cullinan Associates Inc bought 5,820 shares as the company’s stock declined 1.50% while stock markets rallied. The institutional investor held 17,647 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $5.31M, up from 11,827 at the end of the previous reported quarter. Cullinan Associates Inc who had been investing in Biogen Idec for a number of months, seems to be bullish on the $62.99B market cap company. The stock decreased 0.11% or $0.36 during the last trading session, reaching $320.2. About 131,832 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since March 14, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 05/04/2018 – BIOGEN INC – PRECISE TERMS OF AGREEMENT WITH ABBVIE ARE CONFIDENTIAL; 05/04/2018 – BIOGEN INC – COMPANIES HAVE AGREED TO DISMISS ALL PENDING PATENT LITIGATION; 24/04/2018 – Biogen Reports Quarterly Revenues of $3.1 Billion; 19/04/2018 – Biogen at American Academy of Neurology Meeting Apr 25; 05/04/2018 – BIOGEN INC – BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018; 17/05/2018 – Samsung BioLogics said JV partner Biogen to exercise option by late June; 02/05/2018 – Bristol-Myers Squibb and Biogen Are the Pharmas Most Trusted by Doctors, Study Finds; 01/05/2018 – BIOGEN & NEURIMMUNE REPORT OPTION EXERCISE; 24/04/2018 – BIOGEN INC – QTRLY AVONEX REVENUE OF $451 MLN VS $537 MLN REPORTED LAST YEAR; 20/04/2018 – BIOGEN – CO, IONIS EXPANDED COLLABORATION THROUGH NEW 10-YR AGREEMENT TO DEVELOP NOVEL ANTISENSE DRUG CANDIDATES FOR RANGE OF NEUROLOGICAL DISEASES

Willingdon Wealth Management decreased its stake in Johnson & Johnson (JNJ) by 4.69% based on its latest 2018Q4 regulatory filing with the SEC. Willingdon Wealth Management sold 2,889 shares as the company’s stock declined 5.44% while stock markets rallied. The institutional investor held 58,749 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $7.58 million, down from 61,638 at the end of the previous reported quarter. Willingdon Wealth Management who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $368.53B market cap company. The stock decreased 0.72% or $1.01 during the last trading session, reaching $138.4. About 1.42 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 8.80% since March 14, 2018 and is uptrending. It has outperformed by 4.43% the S&P500. Some Historical JNJ News: 21/05/2018 – JANSSEN PHARMACEUTICAL COMPANIES – EUROPEAN COMMISSION GRANTED MARKETING AUTHORISATION FOR JULUCA; 16/03/2018 – Johnson & Johnson Sees Deal Closing by End of 2018 If Offer Accepted; 13/03/2018 – Johnson & Johnson virtual training centers help Asia’s surgeons; 08/05/2018 – GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Decipher® Classifier and Decipher GRID® for Drug Development; 17/04/2018 – Johnson & Johnson To Implement Actions Across Global Supply Chain; 11/05/2018 – Risperdal Consta (Johnson & Johnson): Global Drug Overview & Outlook 2017/2018-2026 – ResearchAndMarkets.com; 15/03/2018 – J&J’s blockbuster hopeful erdafitinib gets ‘breakthrough’ moniker $JNJ @BrittanyMeiling; 14/03/2018 – South Dakota sues opioid makers as litigation swells; 16/05/2018 – J&J CEO warns of ‘unintended consequences’ of Trump’s drug-price reduction plan; 14/05/2018 – STAT Plus: AbbVie and J&J reverse course on a price hike in face of criticism

Since November 7, 2018, it had 3 insider buys, and 6 selling transactions for $74.45 million activity. Kapusta Ronald A also sold $1.23 million worth of Johnson & Johnson (NYSE:JNJ) on Thursday, November 8. The insider PRINCE CHARLES bought $268,731. On Monday, December 3 the insider Fasolo Peter sold $24.41M. 748 shares were bought by MULCAHY ANNE M, worth $100,050 on Friday, December 14. Gorsky Alex sold $38.60 million worth of Johnson & Johnson (NYSE:JNJ) on Friday, November 16. The insider Duato Joaquin sold $5.77M.

Investors sentiment decreased to 0.86 in Q4 2018. Its down 0.19, from 1.05 in 2018Q3. It is negative, as 51 investors sold JNJ shares while 851 reduced holdings. 145 funds opened positions while 631 raised stakes. 1.79 billion shares or 5.17% more from 1.70 billion shares in 2018Q3 were reported. Villere St Denis J Limited stated it has 0.44% of its portfolio in Johnson & Johnson (NYSE:JNJ). Hite Hedge Asset Mgmt Limited Co reported 2,771 shares stake. Marco Invest Limited Com holds 32,830 shares. Perritt Capital Mgmt has 4,676 shares for 0.23% of their portfolio. Blb&B Limited Liability Company holds 129,808 shares. Deltec Asset Management Ltd Co owns 0.12% invested in Johnson & Johnson (NYSE:JNJ) for 3,425 shares. Gabelli Funds Limited Com has 295,200 shares for 0.26% of their portfolio. Cetera Advisor Net Ltd Liability accumulated 0.62% or 123,516 shares. Butensky And Cohen Fincl Security holds 15,512 shares or 1.78% of its portfolio. Woodstock invested in 2.36% or 91,119 shares. Prospector Prtnrs Limited Liability Company stated it has 1.24% of its portfolio in Johnson & Johnson (NYSE:JNJ). Asset Management invested in 1.29% or 162,383 shares. First Foundation Advisors has 1.48% invested in Johnson & Johnson (NYSE:JNJ). Keating Investment Counselors stated it has 59,532 shares or 3.89% of all its holdings. East Coast Asset Mgmt Ltd Limited Liability Company holds 0.53% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 13,340 shares.

Willingdon Wealth Management, which manages about $239.04M and $347.15 million US Long portfolio, upped its stake in Fedex Corp (NYSE:FDX) by 10,207 shares to 10,594 shares, valued at $1.71 million in 2018Q4, according to the filing. It also increased its holding in Nvidia Corp (NASDAQ:NVDA) by 18,072 shares in the quarter, for a total of 18,121 shares, and has risen its stake in 3M Co (NYSE:MMM).

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on April, 16. They expect $2.10 EPS, up 1.94% or $0.04 from last year’s $2.06 per share. JNJ’s profit will be $5.59 billion for 16.48 P/E if the $2.10 EPS becomes a reality. After $1.97 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts 6.60% EPS growth.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “Johnson & Johnson: P/E Matters – Seeking Alpha” on January 17, 2019, also Seekingalpha.com with their article: “J&J extends baby powder crisis slump – Seeking Alpha” published on December 17, 2018, Seekingalpha.com published: “Is Johnson & Johnson A Buy Here? – Seeking Alpha” on November 19, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Novartis sues J&J over “misleading” Tremfya data – Seeking Alpha” published on March 04, 2019 as well as Seekingalpha.com‘s news article titled: “Johnson & Johnson: Paying A Premium For Liability Risk – Seeking Alpha” with publication date: October 17, 2018.

Since September 26, 2018, it had 1 buy, and 1 insider sale for $20.22 million activity. 1,000 shares were sold by Ehlers Michael D, worth $350,000 on Wednesday, September 26.

Cullinan Associates Inc, which manages about $1.27 billion and $1.21 billion US Long portfolio, decreased its stake in Comcast Corp (NASDAQ:CMCSA) by 249,715 shares to 222,089 shares, valued at $7.56 million in 2018Q4, according to the filing. It also reduced its holding in Hasbro Inc (NASDAQ:HAS) by 6,025 shares in the quarter, leaving it with 75,785 shares, and cut its stake in Exxon Mobil (NYSE:XOM).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Nasdaq.com which released: “Health Care Sector Update for 03/04/2019: NITE, BIIB, ASND, AVXL, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” on March 04, 2019, also Nasdaq.com with their article: “Notable ETF Outflow Detected – IBB, BIIB, ILMN, REGN – Nasdaq” published on February 14, 2019, Seekingalpha.com published: “Biogen takes issue with incomplete coverage of Spinraza in Canada – Seeking Alpha” on March 04, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Globenewswire.com and their article: “Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA – GlobeNewswire” published on March 01, 2019 as well as Nasdaq.com‘s news article titled: “Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm – Nasdaq” with publication date: March 12, 2019.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.